- Through its technology Futurs, it acquires 10% of the startup Kenko Imalytics, backed by the Polytechnic University of Valencia (UPV), and with more than ten years of experience in data analysis, from magnetic resonance images
- The objective is to turn this program into a tool that helps radiologists to predict and define, with objective data, the development of a breast lesion, as well as the stage of a tumor and promote Valencian talent from its universities.
- The new software based on imaging biomarkers will include the possibility of diagnosing through a disruptive and innovative virtual biopsy and may reduce false diagnoses in breast cancer to the maximum.
El Ribera healthcare group has invested in software that, with advanced data analytics and artificial intelligence, establishes biomarkers from magnetic resonance images, which configure a "virtual biopsy" for a more accurate diagnosis of breast cancer. Through its technological Futures, Ribera has acquired 10% of the startup Kenko Imalytics, promoter of this program, and which is supported and participated by the Polytechnic University of Valencia (UPV), and with more than ten years of experience in medical imaging research, applying multivariate methods based on latent variables (in statistics, variables that are not directly observed).
This agreement confirms the commitment of the Ribera group to one of its strategic transversal areas, the Breast Area, as well as for open innovation, based on its collaboration with startups that develop projects for the Health sector. In addition, it represents a commitment to Valencian talent linked to universities and, especially, to the desire to reach strategic agreements with the UPV, through its startup accelerator and its Biostatistics group. The university hospitals of Torrejon y Vinalopoas well as hospitals Ribera Polusa, Ribera Povisa and hospital of Denia They are already integrated into the Mama de Ribera Area.
This advanced analysis software allows biomarkers to be protocolized, based on the data analysis of thousands of resonance images and artificial intelligence, with the aim of providing information on breast lesions "at the pixel level", predicting cancer at a very early, accurately determine the grade and present it to the radiologist in an easily interpretable format. The Ribera group participates in the development of this tool through its Breast Area, directed by Dr. Julia Camps, to turn it into a platform that helps radiologists make decisions about breast cancer, thanks to its most recent analyses. precise, contrasted and constantly updated. Dr. Camps recalls that the Ribera hospitals have the best professionals and the most advanced technology for the diagnosis of breast cancer and adds that "tools like this software will allow us to advance in precision medicine and provide patients with the best clinical approach and surgical, in an even more personalized way, based on data analytics and artificial intelligence, which will provide increasingly accurate results”.
For his part, the CEO of Kenko Imalytics, Eric Aguado, pointed out that "this software can reduce false diagnoses, both positive and negative, by a considerable percentage." “In relation to breast cancer, which is one of the malignant tumors that has grown the most globally and in which the most therapeutic progress has been made over the years, we currently have very encouraging results, reaching close to a total reduction of previous erroneous evaluations by physicians and improving the results of the current biomarker software available on the market”, he assures.
When a diagnostic imaging professional uses Kenko's algorithms, "he has before him an effective, agile and intuitive means that allows him to determine a case of breast cancer with greater certainty", according to Aguado, who emphasizes that one of the revolutions of its biomarkers is that it reduces the knowledge gap between Radiology specialists since "in case of suspicion of cancer, using our artificial intelligence means that both a resident and a professional with many years of experience will quickly clear up their doubts" .
